Activation of type I interferon in systemic lupus erythematosus

Expert Review of Clinical Immunology

Volumn 3, Issue 4, 2007, Pages 579-588

  Kirou, Kyriakos A ^a   Mavragani, Clio P ^a   Crow, Mary K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; GAMMA INTERFERON; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; INTERFERON; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SMALL NUCLEAR RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG MECHANISM; DRUG MEGADOSE; GENETIC ASSOCIATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTERFERON INDUCTION; INTERFERON PRODUCTION; NONHUMAN; PARTIAL TRISOMY 9; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34447628866     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.4.579     Document Type: Review

References (99)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147(927), 258-267 (1957).
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004).
3. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366(2), 525-539 (2007).
4. Jaitin DA, Roisman LC, Jaks E et al. Inquiring into the differential action of interferons (IFNs): an IFN-a2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell. Biol. 26(5), 1888-1897 (2006).
5. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75(2), 163-189 (2004).
6. Kotenko SV, Gallagher G, Baurin VV et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4(1), 69-77 (2003).
7. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4(1), 63-68 (2003).
8. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5(8), 919-923 (1999).
9. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284(5421), 1835-1837 (1999).
10. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 25(3), 373-381 (2006).
11. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
12. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006(357), re13 (2006).
13. Honda K, Ohba Y, Yanai H et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434(7036), 1035-1040 (2005).
14. Honda K, Yanai H, Negishi H et al. IRF-7 is the master regulator of type-1 interferon-dependent immune responses. Nature 434(7034), 772-777 (2005).
15. Hoshino K, Sugiyama T, Matsumoto M et al. IΚB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440(7086), 949-953 (2006).
16. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25(3), 349-360 (2006).
17. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115 (1), 196-202 (1999).
18. Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J. Immunol. 163(11), 6306-6313 (1999).
19. Loygren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50(6), 1861-1872(2004).
20. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J. Immunol. 165(6), 3519-3526 (2000).
21. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc γ RIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171(6), 3296-3302 (2003).
22. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115(2), 407-417 (2005).
23. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202(11), 1575-1585 (2005).
24. Savarese E, Chae OW, Trowitzsch S et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107(8), 3229-3234 (2006).
25. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen-and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54(6), 1917-1927 (2006).
26. Kelly KM, Zhuang H, Nacionales DC et al. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/ RNP and Ro 60. Arthritis Rheum. 54(5), 1557-1567 (2006).
27. Rice G, Newman WG, Dean J et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80(4), 811-815 (2007).
28. Crow YJ, Leitch A, Hayward BE et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat. Genet. 38(8), 910-916 (2006).
29. Crow YJ, Hayward BE, Parmar R et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38(8), 917-920 (2006).
30. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erychematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54(6), 1906-1916 (2006).
31. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52(5), 1491-1503 (2005).
32. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312(5780), 1669-1672(2006).
33. Subramanian S, Tus K, Li QZ et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103(26), 9970-9975 (2006).
34. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25(3), 417-428 (2006).
35. Bekeredjian-Ding IB, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174 (7), 4043-4050(2005).
36. + regulatory T cells. J. Immunol. 173 (7), 4433-4442(2004).
37. Sato K, Hida S, Takayanagi H et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31 (11), 3138-3146(2001).
38. Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Induction of Fas ligand-mediated apoptosis by interferon-α. Clin. Immunol. 95(3), 218-226 (2000).
39. Nguyen KB, Salazar-Mather TP, Dalod MY et al. Coordinated and distinct roles for IFN-α β, IL-12, and IL- 15 regulation of NK cell responses to viral infection. J. Immunol. 169(8), 4279-4287 (2002).
40. + T cells in vivo by IL- 15. Immunity 8(5), 591-599 (1998).
41. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200(4), 535-540 (2004).
42. O'Connell RM, Saha SK, Vaidya SA et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 200(4), 437-445 (2004).
43. Mancuso G, Midiri A, Biondo C et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178(5), 3126-3133(2007).
44. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294(5546), 1540-1543 (2001).
45. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
46. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. Cutting edge. the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176(6), 3315-3319 (2006).
47. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272(5270), 1947-1950(1996).
48. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J. Exp. Med. 189(3), 521-530 (1999).
49. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2),225-234 (2003).
50. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4), 461-470 (2001).
51. Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med 202(9), 1171-1177 (2005).
52. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 172(10), 6476-6481(2004).
53. Bauer JW, Baechler EC, Petri M et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 3(12), E491 (2006).
54. Meller S, Winterberg F, Gilliet M et al. Utraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 52(5), 1504-1516(2005).
55. Yarilina. A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol. 178(4), 2204-2211 (2007).
56. Biron CA. Interferons α and β as immune regulators - a new look. Immunity 14(6), 661-4 (2001).
57. Santiago-Raber ML, Baccala R, Haraldsson KM et al. Type-I interferon receptor deficiency reduces lupus-tike disease in NZB mice. J. Exp. Med 197(6), 777-788 (2003).
58. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20(1), 15-25 (2003).
59. Jorgensen TN, Thurman J, Izui S et al. Genetic susceptibility to polyI:C-induced IFNα/β-dependent accelerated disease in lupus-prone mice. Genes Immun. 7(7), 555-567(2006).
60. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J. Immunol. 174(5), 2499-2506 (2005).
61. Hron JD, Peng SL. Type I IFN protects against murine lupus. J. Immunol. 173 (3), 2134-2142 (2004).
62. Schwarting A, Paul K, Tschirner S et al. Interferon-β: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16(11), 3264-3272 (2005).
63. von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol. Int. 8(5), 225-230 (1988).
64. Sibbitt WL Jr, Gibbs DL, Kenny C, Bankhurst AD, Searles RP, Ley KD. Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus. Arthritis Rheum. 28(6), 624-629 (1985).
65. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 25(4), 401-406 (1982).
66. Panem S, Ordonez N, Vilcek J. Renal deposition of α interferon in systemic lupus erythematosus. Infect. Immun. 42(1), 368-373 (1983).
67. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-α in lupus psychosis. Arthritis Rheum. 35 (4), 417-422 (1992).
68. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115(3), 178-183 (1991).
69. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 227(3), 207-210 (1990).
70. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197(6), 711-723 (2003).
71. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100(5), 2610-2615 (2003).
72. Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50(12), 3958-3967 (2004).
73. Zhuang H, Narain S, Sobel E et al. Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin. Immunol. 117(3), 238-250(2005).
74. Peterson KS, Huang JF, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113(12), 1722-1733(2004).
75. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202(8), 1131-1139 (2005).
76. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 10(7), 484-490 (2001).
77. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/ β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J. Pathol. 15(1), 237-243 (2001).
78. Graham DS, Manku H, Wagner S et al. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum. Mol. Genet. 16(6), 579-591 (2006).
79. Graham RR, Kozyrev SV, Baechler EC et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38(5), 550-555 (2006).
80. Sigurdsson S, Nordmark G, Goring HH et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76(3), 528-537 (2005).
81. Zhuang H, Kosboth M, Lee P et al. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p. Arthritis Rheum. 54(5), 1573-1579 (2006).
82. Bave U, Nordmark G, Lovgren T et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 52(4), 1185-1195 (2005).
83. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc. Natl Acad. Sci. USA 103(8), 2770-2775 (2006).
84. James JA, Harley JB, Scofield RH. Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr. Opin. Rheumatol. 13(5), 370-376 (2001).
85. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum. 50(9), 2897-2902(2004).
86. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 52(5), 1534-1544 (2005).
87. Wenzel J, Scheler M, Bieber T, Tuting T. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br. J. Dermatol. 153(2), 462-463; author reply 463-464(2005).
88. Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med. Sci. Monit. 10(7), BR191-BR197 (2004).
89. Tan FK, Zhou X, Mayes MD et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells ofsystemic sclerosis patients. Rheumatology (Oxf.) 45(6), 694-702 (2006).
90. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52(2), 651-658 (2005).
91. Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res. Ther. 8(1), 203 (2006).
92. Patole PS, Zecher D, Pawar RD, Grone HJ, Schlondorff D, Anders HJ. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16(11), 3273-3280 (2005).
93. Davis JC Jr, Manzi S, Yarboro C et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8(1), 68-76 (1999).
94. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum. 48(9), 2524-32 (2003).
95. Abe M, Thomson AW. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin. Immunol. 118(2-3), 300-306 (2006).
96. Lebon E Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J. Gen. Virol. 66 (Pt 12), 2781-2786 (1985).
97. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111(4), 539-552 (2003).
98. Chang HM, Paulson M, Hotko M et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101(26), 9578-9583 (2004).
99. Mbow ML, Sarisky RT. What is disrupting IFN-α's antiviral activity? Trends Biotechnol. 22(8), 395-399 (2004).